XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Research context
XOMA Corporation appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
XOMA Corporation is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.8.
XOMA Corporation's total revenue rose by 6435.5% to $28M since the same quarter in the previous year.
Its net income has increased by 624.6% to $23M since the same quarter in the previous year.
Finally, its free cash flow grew by 497.3% to $16M since the same quarter in the previous year.
Based on the above factors, XOMA Corporation gets an overall score of 4/5.